Delai Chen, PhD

Beam Therapeutics

Delai Chen is an associate director of Nanoparticle Formulation at Beam Therapeutics, leading the development of nonviral delivery technologies for in vivo base editing. Delai has comprehensive experience in the formulation and characterization of nano drug delivery systems and nucleic acids. He started his industrial career at Novartis Vaccines perfecting the use of lipid nanoparticles for self-amplifying mRNA vaccine delivery, a technology currently at Phase I clinical trial. Later on he worked at Codiak Biosciences focusing on analytical development of exosomes as a nano drug delivery system. Delai holds a PhD degree in chemistry from The University of Chicago, and performed postdoctoral research on nanoparticle drug delivery at MIT.